Soumit Roy
Stock Analyst at Jones Trading
(3.03)
# 1,255
Out of 5,242 analysts
44
Total ratings
33.33%
Success rate
18.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Upgrades: Buy | $8 | $2.60 | +207.69% | 2 | Mar 10, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Buy | $7 | $4.22 | +65.88% | 1 | Dec 22, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $7 | $2.23 | +213.90% | 1 | Dec 22, 2025 | |
| EVAX Evaxion | Initiates: Buy | $10 | $4.00 | +150.00% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $2.75 | - | 1 | Oct 24, 2025 | |
| ATYR aTyr Pharma | Downgrades: Hold | n/a | $0.5306 | - | 2 | Sep 15, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $64.76 | -22.79% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $4.76 | +341.18% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $27.22 | +46.95% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $41.86 | -35.50% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.76 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.82 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $3.24 | +362.96% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.51 | +121.73% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $27.11 | +25.41% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.57 | +2,192.99% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $3.56 | +798.88% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $9.97 | -9.73% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $8.41 | +102.14% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $64 | $7.76 | +724.74% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.61 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $14.33 | +81.44% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $14.40 | +386.11% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $64.95 | -84.60% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.02 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.68 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $2.43 | +13,068.72% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $7.18 | +11,181.34% | 1 | Feb 24, 2021 |
Editas Medicine
Mar 10, 2026
Upgrades: Buy
Price Target: $8
Current: $2.60
Upside: +207.69%
Whitehawk Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $4.22
Upside: +65.88%
Context Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $2.23
Upside: +213.90%
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.00
Upside: +150.00%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.75
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.5306
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $64.76
Upside: -22.79%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $4.76
Upside: +341.18%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $27.22
Upside: +46.95%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $41.86
Upside: -35.50%
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.76
Upside: -
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.82
Upside: -
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $3.24
Upside: +362.96%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $4.51
Upside: +121.73%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $27.11
Upside: +25.41%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.57
Upside: +2,192.99%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $3.56
Upside: +798.88%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $9.97
Upside: -9.73%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $8.41
Upside: +102.14%
Sep 11, 2024
Maintains: Buy
Price Target: $96 → $64
Current: $7.76
Upside: +724.74%
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.61
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $14.33
Upside: +81.44%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $14.40
Upside: +386.11%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $64.95
Upside: -84.60%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.02
Upside: -
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.68
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $2.43
Upside: +13,068.72%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $7.18
Upside: +11,181.34%